Most firms to slash R&D spending in 2012 business plan

A majority of Korean pharmaceutical companies are now busy finalizing their business plans for the new year, but their 2012 budget plan will place top priority on slashing their research and developing (R&D) spending as part of efforts to save the administrative and promotional expenses, industry observers said.

The government’s plan to slash the price of about half the insurance-covered dru...